Agency Forms Undergoing Paperwork Reduction Act Review, 71279-71280 [2024-19612]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 170 / Tuesday, September 3, 2024 / Notices
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–19624 Filed 8–30–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–24–1102]
tkelley on LAP7H3WLY3PROD with NOTICES2
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Information
Collection for Tuberculosis Data from
Panel Physicians’’ to the Office of
Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice June 4, 2024
to obtain comments from the public and
affected agencies. CDC received two
comments related to the previous
notice. This notice serves to allow an
additional 30 days for public and
affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
VerDate Sep<11>2014
22:46 Aug 30, 2024
Jkt 262001
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Information Collection for
Tuberculosis Data from Panel
Physicians (OMB Control No. 0920–
1102, Exp. 12/31/2024)—Revision—
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention’s (CDC), National Center for
Emerging and Zoonotic Infectious
Diseases (NCEZID), Division of Global
Migration Health (DGMH), Immigrant
and Refugee Health Branch (IRHB),
requests approval for Revision to an
approved information collection. CDC
requests this data collection approval
for three years.
Respondents for this data collection
request are U.S. panel physicians. Panel
physicians are medically trained,
licensed, and experienced medical
doctors practicing overseas who are
appointed by the local U.S. Embassy or
Consulate General to perform medical
examinations for prospective
immigrants to the United States. More
than 760 panel physicians perform
overseas pre-departure medical
examinations at 333 panel sites, in
accordance with requirements, referred
to as Technical Instructions, provided
by the CDC’s DGMH, Quality
Assessment Program (QAP). The QAP is
housed in the IRHB. The role of QAP is
to assist and guide panel physicians in
the implementation of the Technical
Instructions; evaluate the quality of the
overseas medical examination for U.S.bound immigrants and refugees; assess
potential panel physician sites; and
provide recommendations to the U.S.
Department of State in matters of
immigrant medical screening.
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
71279
Screening for tuberculosis (TB) is a
particularly important component of the
immigration medical exam and allows
panel physicians to diagnose active TB
disease prior to arrival in the United
States. As part of the Technical
Instructions requirements, panel
physicians perform chest x-rays and
laboratory tests that aid in the
identification of tuberculosis infection
(Class B1 applicants) and diagnosis of
active tuberculosis disease (Class A,
inadmissible applicants). CDC uses
these classifications to report new
immigrant and refugee arrivals with a
higher risk of developing TB disease to
U.S. state and local health departments
for further follow-up. Some information
that panel physicians collect as part of
the medical exam is not reported on the
standard Department of State forms (DSforms), thereby preventing CDC from
evaluating TB trends in globally mobile
populations and monitoring program
effectiveness.
In 2007, CDC revised the Tuberculosis
Technical Instructions to include
several new requirements for
Mycobacteria tuberculosis (MTB) testing
and treatment. Important changes
included the requirements for: (1)
sputum cultures in addition to sputum
smears; (2) tuberculin skin tests or
interferon gamma release assays
(beginning in 2009) for certain children
aged 2–14 years examined in countries
where the World Health Organization
(WHO) estimated TB incidence is ≥20
per 100,000 persons; (3) drugsusceptibility testing of positive isolates;
and (4) treatment being delivered as
directly observed therapy (DOT)
throughout the entire course.
Since implementation of these new
Culture and Directly Observed Therapy
TB Technical Instructions (CDOT TB
TI), overseas TB case detection has
increased by an estimated 60% and
allowed U.S. public health programs to
save millions of dollars annually.
Overseas TB screening data (referred to
by DGMH as ‘TB Indicator data’) is
critical to support the continued
analysis of these trends and the
monitoring of TB control efforts in the
U.S. DGMH’s TB Indicator data provides
valuable epidemiologic data on globally
mobile populations and allows CDC to
monitor the effectiveness and impact of
CDC’s Technical Instructions in
diagnosing applicants with TB disease.
This data will be used to:
Æ Improve quality assurance efforts
and monitor proficiency of TB screening
programs overseas
Æ Estimate the impact of the CDOT
TB TI on the immigrant screening
program by analyzing the number of
smear negative/culture positive TB
U:\REGISTER\03SEN1.SGM
03SEN1
71280
Federal Register / Vol. 89, No. 170 / Tuesday, September 3, 2024 / Notices
cases. These cases represent the number
of TB cases that would have been
missed under the old screening
program.
Æ Compare TB Indicator incidence
rates to WHO country-specific TB
incidence rates for internal quality
assessment purposes only.
Æ Detect and resolve problems at
panel sites demonstrating lower than
expected TB detection rates.
Data will primarily be used internally
to monitor program impact, but may
also be shared with state and local
health authorities involved in TB
control. Information dissemination may
include abstract submission to scientific
conferences, including the Union World
Conference on Lung Health, the
National TB Controllers Association and
the Panel Physician Training Summits.
Information will be collected from
each Panel Physician site using a web
form created with REDCap on an annual
basis. The TB-related information that is
sent to CDC is aggregate in nature, and
no personal identifying information (PII)
from any applicant for U.S. immigration
is included. Information to be collected
using the spreadsheet includes:
• number of applicants screened,
• age categories of applicants,
• number of abnormal chest x-rays,
• acid fast bacilli (AFB) smear results,
• mycobacterium tuberculosis (MTB)
cultures,
• drug susceptibility test (DST)
results, and
• TB treatment disposition.
The changes in this Revision include
the additional collection of molecular
testing data. CDC requests OMB
approval for an estimated 999 annual
burden hours. There is no cost to
respondents other than their time to
participate.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Form name
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
International Panel Physicans ........................
TB Indicators REDCap Web Form ................
333
1
3
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–19612 Filed 8–30–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–24–23FN; Docket No. CDC–2024–
0061]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled, Menthol-Flavored Tobacco
Products Policy Evaluation. The
proposed activity aims to collect data on
menthol-flavored tobacco product use,
any tobacco use, quit rates, and product
tkelley on LAP7H3WLY3PROD with NOTICES2
SUMMARY:
VerDate Sep<11>2014
22:46 Aug 30, 2024
Jkt 262001
switching behaviors among adults 18
years of age and older.
DATES: CDC must receive written
comments on or before November 4,
2024.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2024–
0061 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
U:\REGISTER\03SEN1.SGM
03SEN1
]]>Agencies
[Federal Register Volume 89, Number 170 (Tuesday, September 3, 2024)]
[Notices]
[Pages 71279-71280]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-19612]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-24-1102]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Information Collection for Tuberculosis
Data from Panel Physicians'' to the Office of Management and Budget
(OMB) for review and approval. CDC previously published a ``Proposed
Data Collection Submitted for Public Comment and Recommendations''
notice June 4, 2024 to obtain comments from the public and affected
agencies. CDC received two comments related to the previous notice.
This notice serves to allow an additional 30 days for public and
affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Information Collection for Tuberculosis Data from Panel Physicians
(OMB Control No. 0920-1102, Exp. 12/31/2024)--Revision--National Center
for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and Prevention's (CDC), National
Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division
of Global Migration Health (DGMH), Immigrant and Refugee Health Branch
(IRHB), requests approval for Revision to an approved information
collection. CDC requests this data collection approval for three years.
Respondents for this data collection request are U.S. panel
physicians. Panel physicians are medically trained, licensed, and
experienced medical doctors practicing overseas who are appointed by
the local U.S. Embassy or Consulate General to perform medical
examinations for prospective immigrants to the United States. More than
760 panel physicians perform overseas pre-departure medical
examinations at 333 panel sites, in accordance with requirements,
referred to as Technical Instructions, provided by the CDC's DGMH,
Quality Assessment Program (QAP). The QAP is housed in the IRHB. The
role of QAP is to assist and guide panel physicians in the
implementation of the Technical Instructions; evaluate the quality of
the overseas medical examination for U.S.-bound immigrants and
refugees; assess potential panel physician sites; and provide
recommendations to the U.S. Department of State in matters of immigrant
medical screening.
Screening for tuberculosis (TB) is a particularly important
component of the immigration medical exam and allows panel physicians
to diagnose active TB disease prior to arrival in the United States. As
part of the Technical Instructions requirements, panel physicians
perform chest x-rays and laboratory tests that aid in the
identification of tuberculosis infection (Class B1 applicants) and
diagnosis of active tuberculosis disease (Class A, inadmissible
applicants). CDC uses these classifications to report new immigrant and
refugee arrivals with a higher risk of developing TB disease to U.S.
state and local health departments for further follow-up. Some
information that panel physicians collect as part of the medical exam
is not reported on the standard Department of State forms (DS-forms),
thereby preventing CDC from evaluating TB trends in globally mobile
populations and monitoring program effectiveness.
In 2007, CDC revised the Tuberculosis Technical Instructions to
include several new requirements for Mycobacteria tuberculosis (MTB)
testing and treatment. Important changes included the requirements for:
(1) sputum cultures in addition to sputum smears; (2) tuberculin skin
tests or interferon gamma release assays (beginning in 2009) for
certain children aged 2-14 years examined in countries where the World
Health Organization (WHO) estimated TB incidence is >=20 per 100,000
persons; (3) drug-susceptibility testing of positive isolates; and (4)
treatment being delivered as directly observed therapy (DOT) throughout
the entire course.
Since implementation of these new Culture and Directly Observed
Therapy TB Technical Instructions (CDOT TB TI), overseas TB case
detection has increased by an estimated 60% and allowed U.S. public
health programs to save millions of dollars annually. Overseas TB
screening data (referred to by DGMH as `TB Indicator data') is critical
to support the continued analysis of these trends and the monitoring of
TB control efforts in the U.S. DGMH's TB Indicator data provides
valuable epidemiologic data on globally mobile populations and allows
CDC to monitor the effectiveness and impact of CDC's Technical
Instructions in diagnosing applicants with TB disease. This data will
be used to:
[cir] Improve quality assurance efforts and monitor proficiency of
TB screening programs overseas
[cir] Estimate the impact of the CDOT TB TI on the immigrant
screening program by analyzing the number of smear negative/culture
positive TB
[[Page 71280]]
cases. These cases represent the number of TB cases that would have
been missed under the old screening program.
[cir] Compare TB Indicator incidence rates to WHO country-specific
TB incidence rates for internal quality assessment purposes only.
[cir] Detect and resolve problems at panel sites demonstrating
lower than expected TB detection rates.
Data will primarily be used internally to monitor program impact,
but may also be shared with state and local health authorities involved
in TB control. Information dissemination may include abstract
submission to scientific conferences, including the Union World
Conference on Lung Health, the National TB Controllers Association and
the Panel Physician Training Summits.
Information will be collected from each Panel Physician site using
a web form created with REDCap on an annual basis. The TB-related
information that is sent to CDC is aggregate in nature, and no personal
identifying information (PII) from any applicant for U.S. immigration
is included. Information to be collected using the spreadsheet
includes:
number of applicants screened,
age categories of applicants,
number of abnormal chest x-rays,
acid fast bacilli (AFB) smear results,
mycobacterium tuberculosis (MTB) cultures,
drug susceptibility test (DST) results, and
TB treatment disposition.
The changes in this Revision include the additional collection of
molecular testing data. CDC requests OMB approval for an estimated 999
annual burden hours. There is no cost to respondents other than their
time to participate.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
International Panel Physicans....... TB Indicators REDCap 333 1 3
Web Form.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-19612 Filed 8-30-24; 8:45 am]
BILLING CODE 4163-18-P
